340B Drug Pricing Data Should Be Listed On Secure Website, IG Recommends
This article was originally published in The Pink Sheet Daily
Executive Summary
The HHS Inspector General estimates that 340B entities paid an additional $41.1 mil. on outpatient drugs in September 2002 because they could not verify the ceiling price. HRSA has begun updating contact information and 340B participation status in real-time.